The effects of levosimendan on haemodynamics in patients undergoing elective aortic valve replacement (AVR) together with coronary artery bypass grafting (CABG) surgry

INTERVENTION: Trade Name: Simdax Pharmaceutical Form: Pharmaceutical form of the placebo: Intravenous infusion Route of administration of the placebo: Intravenous use CONDITION: Aortic valve dysfunction and coronary artery disease ; MedDRA version: 9.1 Level: LLT Classification code 10011078 Term: Coronary artery disease ; MedDRA version: 9.1 Level: LLT Classification code 10002916 Term: Aortic valve replacement PRIMARY OUTCOME: Main Objective: Primary end point(s): Secondary Objective: INCLUSION CRITERIA: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range